glp-1 drug novo nordisk Fails to Quell Alzheimer's in Trials Lilly launches GLP-1 pill, kicking

In EVOKE and EVOKE+, oral semaglutide lowered several cerebrospinal-fluid markers of Alzheimers pathology, including phosphorylated tau and total tau, by up to roughly 10%, yet produced no measurable slowing of clinical decline

In the SCALE trial, patients receiving liraglutide lost an average 5.6 kg (~12 lbs) more than patients receiving placebo, which translated to a 5.4% body weight loss over the course of 56 weeks (NCT01272219)

coli or yeast cells produce a fusion protein that is enzymatically cleaved to release the peptide) ( [41] ) ( [40] )

The flexible utilization of energy substrates by the normal heart is central to maintaining cardiac function

Our narrative review discussed the CV benefits of GLP-1 RAs in terms of controlling CV risk factors and improving CV outcomes in diabetic and nondiabetic patients regardless of their CV history, and the CV perspectives related to their use in clinical practice

Franco JV, Guo Y, Varela LB, et al